89bio Files Q1 2025 10-Q with Business Updates
| Field | Detail |
|---|---|
| Company | 89bio, Inc. |
| Form Type | 10-Q |
| Filed Date | May 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financial-reporting, agreements
TL;DR
89bio Q1 10-Q filed: Equity plans, Teva & Bibo agreements, warrant offerings detailed.
AI Summary
89bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities, including details on its equity incentive plan and various agreements such as the Teva Agreement and a Collaboration Agreement with Bibo Biopharma Engineering Co., Ltd. The filing also references a Follow-On Offering involving Pre-Funded Warrants.
Why It Matters
This filing provides investors with the latest financial and operational details for 89bio, Inc., crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, 89bio faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- 89bio, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- Teva Agreement (contract) — Mentioned agreement
- Bibo Biopharma Engineering Co., Ltd. (company) — Party to a Collaboration Agreement
- Pre-Funded Warrants (financial_instrument) — Related to a Follow-On Offering
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
What specific agreements are mentioned in the filing?
The filing mentions the Teva Agreement, a Collaboration Agreement with Bibo Biopharma Engineering Co., Ltd., and an ATM Facility.
What type of offering is mentioned in relation to Pre-Funded Warrants?
Pre-Funded Warrants are mentioned in the context of a Follow-On Offering.
What is the fiscal year end for 89bio, Inc.?
The fiscal year end for 89bio, Inc. is December 31.
What is the Standard Industrial Classification code for 89bio, Inc.?
The Standard Industrial Classification code for 89bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 2, 2025 regarding 89bio, Inc..